About Sutro Biopharma, Inc.
https://www.sutrobio.comSutro Biopharma, Inc. operates as clinical stage drug discovery, development, and manufacturing company.
CEO
Jane Chung
Compensation Summary
(Year 2024)
Split Record
| Date | Type | Ratio |
|---|---|---|
| 2025-12-03 | Reverse | 1:10 |
ETFs Holding This Stock
Summary
Showing Top 3 of 18
Ratings Snapshot
Rating : C
Most Recent Analyst Grades
Piper Sandler
Overweight
Wells Fargo
Equal Weight
Citizens Capital Markets
Market Perform
HC Wainwright & Co.
Neutral
Wedbush
Neutral
B of A Securities
Underperform
Grade Summary
Showing Top 6 of 6
Price Target
Institutional Ownership
BLACKROCK INC.
Shares:6.91M
Value:$87.49M
SUVRETTA CAPITAL MANAGEMENT, LLC
Shares:6.49M
Value:$82.14M
KYNAM CAPITAL MANAGEMENT, LP
Shares:5.09M
Value:$64.42M
Summary
Showing Top 3 of 104
About Sutro Biopharma, Inc.
https://www.sutrobio.comSutro Biopharma, Inc. operates as clinical stage drug discovery, development, and manufacturing company.
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q3-2025 | $9.69M ▼ | $58.15M ▼ | $-56.86M ▼ | -586.58% ▼ | $-6.7 ▼ | $-44.55M ▼ |
| Q2-2025 | $63.74M ▲ | $67.09M ▼ | $-11.5M ▲ | -18.04% ▲ | $-1.4 ▲ | $1.07M ▲ |
| Q1-2025 | $17.4M ▲ | $85.91M ▲ | $-75.97M ▼ | -436.62% ▲ | $-9.1 ▼ | $-45.57M ▲ |
| Q4-2024 | $14.81M ▲ | $80.07M ▲ | $-72.44M ▼ | -489.18% ▲ | $-8.8 ▼ | $-59.53M ▼ |
| Q3-2024 | $8.52M | $76.44M | $-48.79M | -572.62% | $-5.9 | $-39.08M |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q3-2025 | $167.59M ▼ | $209.66M ▼ | $296.93M ▲ | $-87.27M ▼ |
| Q2-2025 | $205.13M ▼ | $262.36M ▼ | $294.47M ▼ | $-32.11M ▼ |
| Q1-2025 | $248.97M ▼ | $321.43M ▼ | $347.24M ▲ | $-25.81M ▼ |
| Q4-2024 | $316.89M ▼ | $387.21M ▼ | $342.61M ▲ | $44.6M ▼ |
| Q3-2024 | $388.25M | $451.83M | $340.61M | $111.22M |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q3-2025 | $-56.86M ▼ | $-38.19M ▲ | $39.99M ▲ | $102K ▲ | $1.9M ▲ | $-38.44M ▲ |
| Q2-2025 | $-11.5M ▲ | $-44.72M ▲ | $2.58M ▲ | $-60K ▼ | $-42.2M ▲ | $-44.81M ▲ |
| Q1-2025 | $-75.97M ▼ | $-67.88M ▲ | $-16.26M ▼ | $66K ▲ | $-84.08M ▼ | $-69.06M ▲ |
| Q4-2024 | $-72.44M ▼ | $-71.74M ▼ | $87.49M ▼ | $-24K ▼ | $15.73M ▼ | $-72.81M ▼ |
| Q3-2024 | $-48.79M | $-64.52M | $147.29M | $1.02M | $83.79M | $-65.34M |
Revenue by Products
| Product | Q3-2018 | Q4-2018 | Q2-2025 | Q3-2025 |
|---|---|---|---|---|
 Operating Segments | $0 ▲ | $0 ▲ | $60.00M ▲ | $10.00M ▼ |
 Collaboration Revenue | $0 ▲ | $20.00M ▲ | $0 ▼ | $0 ▲ |
 Other Revenue | $0 ▲ | $0 ▲ | $0 ▲ | $0 ▲ |
CEO
Jane Chung
Compensation Summary
(Year 2024)
Split Record
| Date | Type | Ratio |
|---|---|---|
| 2025-12-03 | Reverse | 1:10 |
ETFs Holding This Stock
Summary
Showing Top 3 of 18
Ratings Snapshot
Rating : C
Most Recent Analyst Grades
Piper Sandler
Overweight
Wells Fargo
Equal Weight
Citizens Capital Markets
Market Perform
HC Wainwright & Co.
Neutral
Wedbush
Neutral
B of A Securities
Underperform
Grade Summary
Showing Top 6 of 6
Price Target
Institutional Ownership
BLACKROCK INC.
Shares:6.91M
Value:$87.49M
SUVRETTA CAPITAL MANAGEMENT, LLC
Shares:6.49M
Value:$82.14M
KYNAM CAPITAL MANAGEMENT, LP
Shares:5.09M
Value:$64.42M
Summary
Showing Top 3 of 104